Semaglutide prescribing information (Ozempic) — regulatory product label: Novo Nordisk A/S. (2023). Ozempic (semaglutide) injection, prescribing information. Retrieved from https://www.novo-pi.com/ozempic.pdf
Clinical pharmacology review (peer-reviewed summary): Madsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011). An overview of once-weekly GLP-1 receptor agonists — pharmacology and clinical use. Journal of Clinical Endocrinology & Metabolism, 96(7), 1804–1813. https://doi.org/10.1210/jc.2010-2709
World Health Organization (WHO). Factsheet: Obesity and overweight. Updated December 2025. Accessed March 2026. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
World Health Organization. Rare diseases: a global health priority for equity and inclusion [online]. Available at: apps.who.int/gb/ebwha/pdf_files/WHA78/A78_R11-en.pdf. Last accessed: January 2026.
The Lancet Global H. The landscape for rare diseases in 2024. Lancet Glob Health. 2024;12(3):e341.
Faye F, Crocione C, Anido de Peña R, et al. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey. Eur J Hum Genet. 2024;32(9):1116-1126.
Boulanger V, Schlemmer M, Rossov S, et al. Establishing Patient Registries for Rare Diseases: Rationale and Challenges. PharmaceutMed. 2020;34(3):185–190.
World Health Organization. Rare diseases: a global health priority for equity and inclusion [online]. Available at: apps.who.int/gb/ebwha/pdf_files/WHA78/A78_R11-en.pdf. Last accessed: February 2026.
Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating the cumulative point prevalence of rare diseases: analysis of the Orphanetdatabase. Eur J Hum Genet. 2020;28:165–173
Efthymiadou O, Mossman J, Kanavos P. Differentiation of health-related quality of life outcomes between five disease areas: results from an international survey of patients. Int J Technol Assess Health Care. 2018;34(5):498–506.
Chan KY, Chan ML. Advancing mental health care and research in rare diseases. Lancet Psychiatry. 2025;12(11):808–809
Faye F, Castro R, Dubief J. The impact of living with a rare disease: barriers and enablers of independent living and social participation. A Rare Barometer survey [online]. Available at: download2.eurordis.org/rarebarometer/RB_Impact_Living_RD_report.pdf. Last accessed: February 2026.
https://www.worldobesityday.org/ Last accessed: 2 February 2026
Vahdatpour S, Mamaghani A, Goloujeh MS, et al. The systematic review of proteins digestion and new strategies for delivery of small peptides. Electronic J Biol. 2016;12:265–275.
Santulli G. From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovascular Diabetology – Endocrinology Reports. 2025;11:31. Doi: 10.1186/s40842-025-00245-5.
Friedman JM. The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proc Natl Acad Sci U S A. 2024;121:e2415550121. doi: 10.1073/pnas.241555012.
Wong HJ, Sim B, Teo YH, et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care. 2025;48:292–300. doi: 10.2337/dc24-1678.
International Diabetes Federation. IDF Atlas 10th Edition, 2021. Available from: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf. Last accessed: December 2025.
EMA. Ozempic® (once-weekly semaglutide) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic. Last accessed: December 2025.
EMA. Wegovy® (semaglutide injection 2.4 mg). Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf. Last accessed: December 2025.
EMA. Rybelsus® (oral semaglutide) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus. Last accessed: December 2025.
WHO. Obesity and Overweight. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Last accessed: December 2025.
Kushner RF, Jastreboff AM and Ryan DH. Current and Future Medications for Obesity Treatment. JAMA. 2025;334(17):1551–1552.
Park C, Kim Y, Raygani S, et al. A glimpse into the pipeline of anti obesity medication development: Combining multiple receptor pathways. Frontiers in Endocrinology. 2025;16:1630199
Phelps NH, Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–1050.
Pathak R, Gaur V, Sankrityayan H, et al. Tackling Counterfeit Drugs: The Challenges and Possibilities. Pharmaceut Med. 2023;37:281-290.
Safe Online Pharmacies, https://safe.pharmacy/buy-safely (accessed Dec 2025)
ASOP is a recognized partner of authorities & industry in the fight against counterfeit
ASOP-Global-Foundation-2021-Consumer-Behavior-Survey-Key-Findings_Final-7.9.2021.pdf (from page 2: “Yet, of the roughly 35,000 online pharmacies worldwide, 95% operate illegally, in violation of state and/or federal law and relevant pharmacy practice standards, including selling medicines without requiring a prescription and operating without a pharmacy license.”)
World Health Organization: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
International Diabetes Federation. 11th Edition | 2025 Diabetes Atlas [online]. Available at: diabetesatlas.org/resources/idf-diabetes-atlas-2025/ Last accessed: October 2025
Handelsman Y, Anderson JE, Bakris GL, et al. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024;159:155931.
American Heart Association Newsroom. 1 in 3 adults with Type 2 diabetes may have undetected cardiovascular disease (2023) [online]. Available at: newsroom.heart.org/news/1-in-3-adults-with-type-2-diabetes-may-have-undetected-cardiovascular-disease Last accessed: October 2025
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease [online] (2022). Available at: https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Ma… Last accessed: October 2025.
Rivera FB, Linnaeus LA, Cruz JVM, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. American Journal of Preventive Cardiology. 2024;18:2666-6677.
Genua I, Cusi K. Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies. Diabetes Spectr. 2024;37(1):48-58.
Islam K, Islam R, Nguyen I, et al. Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments. Adv Ther. 2025;42:2659–2678.
Lambrinoudaki I, et al. EMAS position statement: managing obese postmenopausal women. Maturitas. 2010;66(3):323-326.
Knight MG, et al. Weight Regulation in Menopause. Menopause. 2021;28(8):960-965.
Hill K. The demography of menopause. Maturitas. 1996;23(2):113-127.
Palacios Set al. Obesity and menopause. Gynecological Endocrinology. Endocrinology.
Kamińska MS et al. Menopause Predisposes Women to Increased Risk of Cardiovascular Disease. / Clin Med 2023;12(22):7058.
Harper JC et al. An online survey of perimenopausal women to determine their attitudes and knowledge of the menopause. Womens Health (Lond Engl). 2022;18:17455057221106890.
Opoku AA et al. Obesity and menopause. Best Practice & Research Clinical Obstetrics 8 Gynaecology. 2023;88:102348
Vincent C et al. Disordered eating behaviours during the menopausal transition: a systematic review. Appl Physio/ Nutr Metab. 2024;49(10):1286-1308.
Chopra Set al. Weight Management Module for Perimenopausal Women: A Practical Guide for Gynecologists / Midlife Health. 2019;10(4):165-172.
Anagnostis Pet al. Menopause-associated risk of cardiovascular disease. Endor Connect. 2022;11(4):210537.
Handelsman Y, Anderson JE, Bakris GL, et al. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024;159:155931.
Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73:19-33.
Khafagy R, Dash S. Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. Front Cardiovasc Med. 2021;8:768119.
Vanni E, Marengo A, Mezzabotta L, et al. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. Semin Liver Dis. 2015;35:236-249.
Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292:2495-2499.
Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164:1422-1426.
Jankowski J, Floege J, Fliser D, et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143:1157-1172.
International Diabetes Federation. IDF Atlas 10th Edition, 2021. Available from: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf. Last accessed: August 2023.
EMA. Rybelsus® (oral semaglutide) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus. Last accessed: August 2023.
EMA. Ozempic® (once-weekly semaglutide) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic. Last accessed: August 2023.
EMA. Wegovy® (semaglutide injection 2.4 mg). Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf. Last accessed: August 2023.
Drucker DJ and Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023.
Gabery S, Salinas CG, Paulsen SJ et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020 Mar 26;5(6):e133429.
Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23:754-762.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-1844.
Novo Nordisk. Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166301. Last accessed: August 2023.
ClinicalTrials.gov. Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. Available at: https://clinicaltrials.gov/ct2/show/NCT02970942 Last accessed: August 2023.
Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64:399-408.
Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-690.
Lee Y, Lai HTM, Otto MCdO, et al. Serial Biomarkers of De Novo Lipogenesis Fatty Acids and Incident Heart Failure in Older Adults: The Cardiovascular Health Study. Journal of the American Heart Association. 2020;9:e014119.
Dhurandhar, E. J., Maki, K. C. et al. (2025). Food noise: Definition, measurement, and future research directions. Nutrients, 15, 30. Accessed via: https://pmc.ncbi.nlm.nih.gov/articles/PMC12238327/#:~:text=Abstract,%2C%20mental%2C%20or%20physical%20problems
Hayashi, D., Edwards, C. et al. (2023). What is food noise? A conceptual model of food cue reactivity. Nutrients, 15(22), 4809. Accessed via: https://pmc.ncbi.nlm.nih.gov/articles/PMC10674813/
Novo Nordisk Annual report (2020). 16. Available at Novo-Nordisk-Annual-Report-2020.pdf
Masson-Delmotte, V., P. Zhai, H.-O. Pörtner, et al, Summary for Policymakers. In: Global Warming of 1.5°C. Cambridge University Press, Cambridge, UK and New York, NY, USA, 2018; 9. Available at https://doi.org/10.1017/9781009157940.001. Last accessed: July 2025.
Masson-Delmotte, V., P. Zhai, H.-O. Pörtner, et al, Summary for Policymakers. In: Global Warming of 1.5°C. Cambridge University Press, Cambridge, UK and New York, NY, USA, 2018; 9. Available at https://doi.org/10.1017/9781009157940.001. Last accessed: July 2025.
Novo Nordisk. Zero Environmental Impact. Available at Zero environmental impact | We are adopting a circular mindset. Last accessed: July 2025.
Salim, I et al. (2019). Assessing the environmental sustainability of glucose from wheat as a fermentation feedstock: Journal of Environmental Management 247, 323-332.
USDA. World Agricultural Production. Foreign Agricultural Service. Circular Series WAP 07-25. Available at: https://apps.fas.usda.gov/psdonline/circulars/production.pdf Last accessed: July 2025.
SAI. (2023). SAI Platform’s Regenerating Together framework v1.1. Available at: https://saiplatform.org/resource-centre/rtp/ Last accessed: July 2025.
SAI. (2025). A Global Framework for Regenerative Agriculture. Outcome Quantification Guide v1.0. Available at: https://saiplatform.org/resource-centre/rtp/ Last accessed: July 2025.
SAI. (2025). A Global Framework for Regenerative Agriculture. Outcome Quantification Guide v1.0. Available at: https://saiplatform.org/resource-centre/rtp/ Last accessed: July 2025.
SAI. (2025). Towards Regeneration. Deciphering the Relationships between Agricultural Practices and Regenerative Outcomes. Available at: https://saiplatform.org/resource-centre/rtp/ Last accessed: July 2025.
NIAB. (2025). A Global Framework for Regenerative Agriculture. Linking agriculture practices to regenerative agriculture outcomes. Available at: https://saiplatform.org/resource-centre/rtp/ Last accessed: July 2025.
Novo Nordisk. Our Approach to Sustainability. Available at : https://www.novonordisk.com/about/our-approach-to-sustainability.html#
Novo Nordisk Annual report (2024). 60 - 63. Available at Annual Report 2024
Novo Nordisk. Sustainable Business. Available at https://www.novonordisk.com/sustainable-business/zero-environmental-impact/reducing-our-plastic-footprint.html Last accessed: July 2025.
Knight, M. G., et al. (2021). Weight regulation in menopause. Menopause, 28(8), 960–965.
Novo Nordisk. Sustainable Business. Available at https://www.novonordisk.com/sustainable-business/zero-environmental-impact/reducing-our-plastic-footprint.html Last accessed: July 2025.
Hewagalamulage, S. D., Lee, T. K., Clarke, I. J., & Henry, B. A. (2016). Stress, cortisol, and obesity: A role for cortisol responsiveness in identifying individuals prone to obesity. Domestic Animal Endocrinology, 56 (Suppl), S112–S120.
Kahn, B. B., & Flier, J. S. (2000). Obesity and insulin resistance. The Journal of Clinical Investigation, 106(4), 473–481.
Laurberg, P., Knudsen, N., Andersen, S., Carlé, A., Bülow Pedersen, I., & Karmisholt, J. (2012). Thyroid function and obesity. European Thyroid Journal, 1(3), 159–167.
Lobstein et al. (2024). World obesity atlas 2024. World Obesity Federation.
Lobstein et al. (2024). World obesity atlas 2024. World Obesity Federation.
Obesity statistics 2026: https://www.worldobesityday.org/ (accessed 3 Feb 2026)
Lizcano, F., & Guzmán, G. (2014). Estrogendeficiency and the origin of obesity during menopause. Biomed Research International, 2014, Article 757461.
Stachenfeld, N. S. (2014). Hormonal changes during menopause and the impact on fluid regulation. Reproductive Sciences, 21(5), 555–561.
Knight, M. G., et al. (2021). Weight regulation in menopause. Menopause, 28(8), 960–965.
Greendale, G. A., et al. (2019). Changes in body composition and weight during the menopause transition. JCI Insight, 4(5), e124865.
Hewagalamulage, S. D., Lee, T. K., Clarke, I. J., & Henry, B. A. (2016). Stress, cortisol, and obesity: A role for cortisol responsiveness in identifying individuals prone to obesity. Domestic Animal Endocrinology, 56 (Suppl), S112–S120.
Kahn, B. B., & Flier, J. S. (2000). Obesity and insulin resistance. The Journal of Clinical Investigation, 106(4), 473–481.
Laurberg, P., Knudsen, N., Andersen, S., Carlé, A., Bülow Pedersen, I., & Karmisholt, J. (2012). Thyroid function and obesity. European Thyroid Journal, 1(3), 159–167.
Kaufmann B, Boulle P, Berthou F, et al. Heat-stability study of various insulin types in tropical temperature conditions: New insights towards improving diabetes care. PLoS One. 2021;16(2):e0245372.
Actrapid® (human insulin). Summary of Product Characteristics. 2022 [online]. Available at: https://www.ema.europa.eu/en/documents/product-information/actrapid-epar-product-information_en.pdf Last accessed: July 2025.
Insulatard® (human insulin). Summary of Product Characteristics. 2022 [online] Available at: ema.europa.eu/en/documents/product-information/insulatard-epar-product-information_en.pdf Last accessed: July 2025.
National Institutes of Health. Clinical Guidelines On The Identification, Evaluation, And Treatment Of Overweight And Obesity In Adults. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf.
Burke, J. S., Bild, D. E., Hilner, J. E., & et al. (2010). Differences in weight gain in relation to race, gender, age, and education in young adults: The CARDIA study. [Journal Name], [Volume Number], 327-335.
Ruth McPherson. Genetic contributors to obesity. Can J Cardiol. 2007 Aug; 23 (Suppl A): 23A–27A. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787002/
Alexandra Lee, Michelle Cardel, William T Donahoo. Social and Environmental Factors Influencing Obesity. Available at: https://www.ncbi.nlm.nih.gov/books/NBK278977/
Alexandros N Vgontzas 1, Edward O Bixler, George P Chrousos. Obesity-related sleepiness and fatigue: the role of the stress system and cytokines. Ann N Y Acad Sci. 2006 Nov;1083:329-44. doi: 10.1196/annals.1367.023.
Lobstein et al. (2024). World obesity atlas 2024. World Obesity Federation.
Ryan, D. H., & Yockey, S. R. (2017). Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Current Obesity Reports, 6(2), 187–194.
Centers for Disease Control and Prevention. (n.d.). Lifestyle change program. https://www.cdc.gov/diabetes/hcp/lifestyle-change-program/index.html
Finer, N. (2021). Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes, Obesity and Metabolism.